TL;DR Verdict
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, but patients and providers widely use it off-label for weight loss, where it produces results identical to Zepbound. The SURMOUNT-1 trial published in the New England Journal of Medicine showed 20.9% average body weight loss at the 15 mg dose over 72 weeks. Patient reviews are overwhelmingly positive for weight loss efficacy, though dealing with insurance coverage for off-label use and understanding the relationship between Mounjaro and Zepbound creates confusion for many patients.
How Effective Is Mounjaro for Weight Loss?
Mounjaro produces an average body weight reduction of 20.9% at the 15 mg dose over 72 weeks, based on SURMOUNT-1 trial data published in the New England Journal of Medicine. This is compounded formulations of the active ingredient (tirzepatide) and the same clinical data that supports Zepbound. The only difference is the FDA indication: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management.
In the SURPASS trial program (Mounjaro's diabetes-focused trials), tirzepatide also demonstrated significant weight loss alongside blood sugar improvements. SURPASS-1 through SURPASS-5 showed consistent A1C reductions of 1.8 to 2.4 percentage points along with body weight reductions of 12 to 15% in patients with type 2 diabetes.
For patients without diabetes, the SURMOUNT data is more relevant. A 250-pound patient on the 15 mg dose could expect to lose approximately 52 pounds over 72 weeks, with 57% of participants in the trial losing 20% or more of their starting weight.
| Trial | Population | Duration | Avg. Weight Loss (15 mg) | Key Finding |
|---|---|---|---|---|
| SURMOUNT-1[1] | 2,539 adults[1] with obesity (no diabetes) | 72 weeks | 20.9% | 57% lost 20%+ body weight |
| SURMOUNT-2[2] | 938 adults with obesity + T2D | 72 weeks | 14.7% | Combined weight + A1C improvement |
| SURMOUNT-3[3] | 579 adults + behavioral therapy | 72 weeks | 26.6% | Highest weight loss with lifestyle changes |
| SURMOUNT-4[4] | 670 adults, withdrawal design | 88 weeks | Maintained ~20% loss | Patients who stopped regained 14% |
| SURPASS-1[5] | 478 adults with T2D | 40 weeks | 12.0% | Diabetes-focused trial |
The SURMOUNT-3 result is particularly striking. When tirzepatide was combined with intensive behavioral therapy (structured diet and exercise programs), average weight loss reached 26.6%. That number exceeds the typical weight loss from gastric banding surgery and approaches the results of gastric sleeve procedures.
What Do Patients Report About Mounjaro?
Patient reviews of Mounjaro for weight loss are overwhelmingly positive, with satisfaction ratings averaging above 85% on platforms like Drugs.com and patient community forums, based on aggregated user reviews through early 2026. The dual GLP-1/GIP mechanism appears to produce strong appetite suppression with what many patients describe as a "smoother" experience compared to GLP-1-only drugs. For a complete cost breakdown, see our top compounding pharmacies for tirzepatide.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
A recurring theme in Mounjaro patient reviews is the confusion around its relationship with Zepbound. Many patients started Mounjaro for weight loss through a diabetes-related prescription or off-label use, then faced questions about whether to switch to Zepbound. In practice, patients report identical experiences with both since the medication is the same.
The most enthusiastic reviews come from patients who previously tried semaglutide-based medications (Ozempic or Wegovy) and then switched to Mounjaro. Many report greater weight loss, better appetite control, and fewer GI side effects after switching, though individual responses vary widely.
Positive Review Themes
- Superior appetite suppression: Patients frequently describe Mounjaro's hunger control as stronger and more consistent than semaglutide.
- Faster visible results: Many patients report noticeable changes within the first 6 to 8 weeks, faster than their experience with other GLP-1 drugs.
- Dual benefit for diabetic patients: Patients with type 2 diabetes praise the simultaneous improvement in blood sugar and body weight.
- Reduced food noise: Like other GLP-1 medications, the reduction in constant food-related thoughts is highly valued.
- Improved energy levels: As weight comes off and blood sugar stabilizes, patients commonly report better day-to-day energy.
Negative Review Themes
- Insurance confusion: Getting Mounjaro covered for weight loss (rather than diabetes) is a major pain point for many patients.
- GI side effects at dose increases: Nausea, diarrhea, and constipation are common during titration, similar to other GLP-1 medications.
- Injection pen issues: Some patients report occasional issues with the KwikPen autoinjector, including incomplete doses or difficulty with the mechanism.
- Cost without insurance: At roughly $1,060 per month, uninsured patients face significant barriers.
- Uncertainty about off-label use: Patients without diabetes sometimes worry about the legal or medical implications of using a diabetes drug for weight loss.
Mounjaro Side Effects: What Patients Actually Experience
The most common Mounjaro side effects mirror those of Zepbound, since the medication is identical. Nausea affects approximately 18 to 24% of patients, diarrhea affects 13 to 18%, and constipation affects 6 to 11%, with higher rates at higher doses, according to FDA prescribing information for tirzepatide. These rates are generally lower than those reported with semaglutide-based medications.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Patient reviews confirm that GI side effects are dose-dependent and temporary for the majority of users. The titration schedule (starting at 2.5 mg and increasing every 4 weeks) is designed to minimize discomfort, and most patients report that their body adjusts within 1 to 3 weeks of each dose increase.
One side effect that generates significant discussion in Mounjaro patient communities is "sulfur burps," a distinctive rotten-egg-smelling belching that some patients experience. While not listed as a primary side effect in trial data, it appears frequently enough in patient reviews to warrant mention. Most patients find it resolves with dietary adjustments.
| Side Effect | Trial Incidence (10 to 15 mg) | Patient-Reported Severity | Typical Duration |
|---|---|---|---|
| Nausea | 18 to 24% | Mild to moderate | 1 to 3 weeks per dose step |
| Diarrhea | 13 to 18% | Mild | 1 to 2 weeks |
| Decreased appetite | 12 to 20% | Viewed as positive | Persistent (desired effect) |
| Constipation | 6 to 11% | Mild to moderate | Variable |
| Injection site reactions | 3 to 7% | Mild | Minutes to hours |
| Sulfur burps | Not formally reported | Mild but annoying | Variable. improves with diet changes |
| Hair thinning | 5.7% (SURMOUNT data) | Mild to moderate | Temporary (months 3 to 6) |
Serious side effects are rare. Pancreatitis was reported in less than 0.3% of trial participants. Mounjaro carries the same boxed warning about thyroid C-cell tumors as other GLP-1 medications, based on animal data with no confirmed human cases.
Is Mounjaro Worth the Cost for Weight Loss?
Mounjaro carries a list price of approximately $1,060 per month without insurance, the same as Zepbound since both are manufactured by Eli Lilly and contain the same drug at the same doses, according to Eli Lilly's published pricing. The key cost difference is in insurance coverage: Mounjaro may be covered under a diabetes benefit, while Zepbound requires weight management coverage.
For patients with type 2 diabetes, Mounjaro is often easier to get covered by insurance than Zepbound. The diabetes indication means it falls under a different formulary tier, and many insurance plans have established coverage for diabetes medications. Patients without diabetes face a more complicated path.
Compounded tirzepatide offers compounded formulations of the active ingredient at a lower cost. Providers like FormBlends offer compounded tirzepatide starting at $149 per month with medical provider oversight included. This is an option for patients who can't access or afford brand-name Mounjaro or Zepbound.
Disclosure: FormBlends is a licensed telehealth provider that offers compounded tirzepatide. This article is an independent drug review, and our clinical assessments are based on published trial data regardless of the medications we offer.
| Option | Monthly Cost | Notes |
|---|---|---|
| Mounjaro (brand, no insurance) | ~$1,060 | Eli Lilly list price |
| Mounjaro (with diabetes insurance coverage) | $25 to $150 | Often easier to get approved than Zepbound |
| Mounjaro savings card | $0 to $25 | For eligible commercially insured patients |
| Zepbound (brand, weight loss indication) | ~$1,060 | Same drug, different indication |
| Compounded tirzepatide (FormBlends) | $149/mo | Same active ingredient. not brand-name |
Mounjaro vs. Zepbound: Understanding the Difference
Mounjaro and Zepbound contain the exact same medication (tirzepatide) at the exact same doses, manufactured by the same company (Eli Lilly), according to FDA labeling for both products. The only difference is the approved indication: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. From a clinical perspective, patients taking either one are receiving identical treatment.
The distinction matters primarily for insurance and regulatory purposes. A patient with type 2 diabetes may find it easier to get Mounjaro covered. A patient without diabetes may need Zepbound for insurance approval, though some providers prescribe Mounjaro off-label for weight loss when Zepbound coverage is unavailable.
Patient reviews confirm that the experience is identical regardless of which brand name is on the box. Side effects, weight loss trajectory, and appetite suppression are the same because the drug is the same.
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Available doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Manufacturer | Eli Lilly | Eli Lilly |
| Insurance pathway | Diabetes formulary | Weight management formulary |
| Avg. weight loss (15 mg) | 20.9% (SURMOUNT data) | 20.9% (SURMOUNT data) |
| List price | ~$1,060/mo | ~$1,060/mo |
For a complete comparison of all GLP-1 options, see our semaglutide vs. alternatives guide and our tirzepatide for weight loss overview.
Frequently Asked Questions About Mounjaro
Can you use Mounjaro for weight loss without diabetes?
Yes, though it would be considered off-label use. Mounjaro is FDA-approved only for type 2 diabetes. Zepbound, which contains the identical medication, is approved for weight management.
Many providers prescribe Mounjaro off-label for weight loss when Zepbound isn't available or not covered by insurance.
How much weight can you lose on Mounjaro?
The SURMOUNT-1 trial showed average weight loss of 20.9% at the 15 mg dose over 72 weeks. For a 250-pound patient, that's roughly 52 pounds. Even the 5 mg dose produced a 15% average reduction.
Is Mounjaro the same as Zepbound?
Yes, they contain the exact same drug (tirzepatide) at the same doses, made by the same manufacturer (Eli Lilly). The only difference is the FDA-approved indication: Mounjaro for diabetes, Zepbound for weight management.
What are the most common Mounjaro side effects?
Nausea (18 to 24%), diarrhea (13 to 18%), and decreased appetite (12 to 20%) are the most common. These are typically mild to moderate, occur during dose increases, and improve within a few weeks.
Does insurance cover Mounjaro for weight loss?
Most insurance plans cover Mounjaro for type 2 diabetes, but coverage for off-label weight loss use is inconsistent. Some providers can work with insurance companies to obtain coverage, but many patients end up paying out of pocket or switching to Zepbound.
How long does Mounjaro take to work for weight loss?
Most patients notice appetite reduction within 1 to 2 weeks. Visible weight loss typically appears by weeks 4 to 8. Peak weight loss velocity usually occurs between months 3 and 9 as doses increase to therapeutic levels.
What happens if you stop taking Mounjaro?
The SURMOUNT-4 trial showed that patients who stopped tirzepatide regained an average of 14% of their body weight over the following year. Continuing treatment alongside sustainable lifestyle changes is recommended for maintaining results.
Is Mounjaro better than Wegovy?
Mounjaro (tirzepatide) produces greater average weight loss than Wegovy (semaglutide), approximately 20.9% versus 14.9% in clinical trials. But Wegovy has stronger cardiovascular outcomes data from the SELECT trial[6]. The best choice depends on individual health factors, response, and insurance coverage.
For additional resources, see our Zepbound before-and-after results, tirzepatide side effects guide, and semaglutide reviews.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide with intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2024. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155. [PubMed | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →